Sign up
Pharma Capital

ResApp Health director provides share support through on-market buying

ResApp has adult and paediatric clinical studies underway in the U.S. and Australian.
ResApp shares are up today

ResApp Health Ltd's (ASX:RAP) executive director, Brian Leedman, has provided support for the company's valuation through the purchase of 876,000 shares on-market this week for a consideration of $64,500.

Leedman's stake in the company is now 21.5 million shares, along with 18.75 million performance shares and several lines of director incentive options.

A separate company holding has 4.5 million shares, along with the same number of performance shares.

ResApp has a business strategy of developing smartphone applications for the diagnosis and management of respiratory disease.

Shares in the company have climbed 9.3% today to $0.082. A year earlier shares were trading in the mid $0.40 range.

Register here to be notified of future RAP Company articles
View full RAP profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.